

Please type a plus sign (+) inside this box →



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO <div style="text-align: center;"> INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) </div>		Complete if Known RECEIVED Application Number 09/882,843 JUN 26 2002 TECH CENTER 1600/2900 Filing Date June 15, 2001 First Named Inventor Xue-Feng Pei Group Art Unit 1614 1624 Examiner Name COLEMAN Attorney Docket Number SYM 114	
Sheet	1	of	3

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
BC		5,716,956		Pelletier	02-10-1998	class 514 subclass 248

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office. ³	Number ⁴	Kind Code ⁵ (if known)				

Examine Signature	Brenda Coleman	Date Considered	Sept. 23, 2002
-------------------	-----------------------	-----------------	-----------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.


Please type a plus sign (+) inside this box →



PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

RECEIVED

Substitute for form 1449A/PTO		C m p l t i f K n w n JUN 2 6 2002	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)		Applicati n Number	09/882,843 TECH CENTER 1600/2900
		Filing Date	June 15, 2001
		First Named Inventor	Xue-Feng Pei
		Group Art Unit	4644 1604
		Examiner Name	COLEMAN
Sheet 2	3	Attorney Docket Number	SYM 114

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
BC		CHEN, "Evaluation of five methods for testing anticonvulsant activities," <i>Proc. Soc. Exp. Biol. Med.</i> 87:334 (1954).	
BC		DONEVAN & ROGAWSKI, "GYKI 52466, a 2,3-benzodiazepine, is a highly selective, noncompetitive antagonist of AMPA/kainate receptor responses," <i>Neuron</i> 10:51-59 (1993).	
BC		HUSSY, et al., "Functional properties of a cloned 5-hydroxytryptamine 1onotropic receptor subunit: Comparison with native mouse receptors," <i>J. Physiol. (London)</i> 481(2):311-323 (1994).	
BC		LE PEILLET, et al., "The non-NMDA antagonists, NBQX and GYKI 52466, protect against cortical and striatal cell loss following transient global ischaemia in the rat," <i>Brain Res.</i> 571:115-120 (1992).	
BC		LIPTON & ROSENBERG, "Excitatory amino acids as a final common pathway for neurologic disorders," <i>New England Journal of Medicine</i> 330:613-622 (1994).	
BC		MCBURNEY, "Therapeutic potential of NMDA antagoniate in neurodegenerative diseases," <i>Neurobiology of Aging</i> 15:271-273 (1994).	
BC		MELDRUM & SMITH, "Cerebroprotective effect of a non-N-methyl-D-aspartate antagonist, GYKI 52466, after focal ischemia in the rat," <i>Stroke</i> 23:861 (1992).	
BC		MELDRUM, "Excitatory amino acids in epilepsy and potential novel therapies," <i>Epilepsy Research</i> 12:189-196 (1992).	
BC		Remington's Pharmaceutical Sciences 17th Edition, p. 1418 (1985).	
BC		TARNAWA, et al., "Electrophysiological studies with a 2,3-benzodiazepine muscle relaxant: GKYI 52466," <i>Eur. J. Pharmacol</i> 167:193-199 (1989).	

Examiner's Signature	Brenda Coleman	Date Considered	Sept. 23, 2002
----------------------	----------------	-----------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

0

+



+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

C mplete if Kn wn

RECEIVED

Application Number

09/882.843

JUN 26 2002

(use as many sheets as necessary)

TECH CENTER 1600/2900

Filing Date

June 15, 2001

First Named Inventor

Xue-Feng Pei

Group Art Unit

1014	1624
------	------

Examiner Name

COLEMAN

Attorney Docket Number

SYM 114	
---------	--

Sheet

3

of

3

[illegible]

Examiner's
Signature

Brenda Coleman

Date Considered

Sept. 23, 2002

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.